Bristol-Myers
Squibb Company (NYSE: BMY) today announced that Frances Heller will
join the company as senior vice president, Business Development, on
October 1, 2012. She will report to Lamberto Andreotti, chief executive
officer, and will be a member of the company’s Senior Management Team.
“With broad experience across both the biotech and pharmaceutical
industries, I believe Fran will be an important addition to my diverse
management team and to the company,” said Lamberto
Andreotti, chief executive officer, Bristol-Myers Squibb. “In
addition, her scientific, business and legal background, as well as her
experience across therapeutic areas, will help Bristol-Myers Squibb
continue to execute its strategy of finding external innovation that
complements our own internal R&D pipeline and helps us bring important
new medicines to patients.”
Prior to joining Bristol-Myers Squibb, Ms. Heller was executive vice
president, Business Development at Exelixis, where she accomplished
several large, company-transforming transactions. Prior to that, Ms.
Heller was head of Strategic Alliances at Novartis Pharmaceuticals where
she was responsible for transactions with partners in the pharmaceutical
and biotech industry as well as academic institutions worldwide.
Previously, she was Corporate and Intellectual Property counsel for
Celera Genomics. Ms. Heller serves on the board of directors of several
biotech companies and universities, is a Trustee at the Dana Farber
Cancer Institute and teaches a business class at Stanford University on
the biotech and pharmaceutical industry.
“I am excited by the opportunity to join Bristol-Myers Squibb and its
Senior Management Team,” said Ms. Heller. “Bristol-Myers Squibb is well
known and respected for integrating business development as a key
component of its strategy. I am looking forward to joining a team that
is committed to continuing to build a differentiated capability in
evaluating, securing and maintaining innovative transactions.”
Ms. Heller is a member of the California State Bar, is licensed by the
U.S. Patent and Trademark Office, and has a B.S. in biology from Tulane
University, an M.A. in biology from American University, and a J.D. from
Golden Gate University School of Law.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information, please
visit www.bms.com
or follow us on Twitter at http://twitter.com/bmsnews.

Bristol-Myers SquibbMedia:Jennifer Fron Mauer, 609-252-6579jennifer.mauer@bms.comorInvestors:John Elicker, 609-252-4611john.elicker@bms.com